A Phase 3 interventional study of Vitamin-D in COVID-19 Respiratory Infection, sponsored by Sulaimany Polytechnic university. Completed at 1 site in Iraq. Open to participants aged 30 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-12.
Sponsored by Sulaimany Polytechnic university · Phase 3, Interventional, and Supportive care
The goal of this clinical trial study is to investigate the role of anthropometric indices and Vit-D supplementation on BioNTech, Pfizer vaccine side effect and immunoglobulin G response against SARS-CoV-2 in individuals infected with COVID-19.
The main question[s] it aims to answer are:
The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast, for 14-16 weeks. The control group took a placebo prepared with the same shape and size of supplements. The supplement was given to the patients by someone other than the researcher, to ensure that the researchers did not know which group receiving the supplement/placebo (given the double-blindness of the study). Also, in this study, the person who did the data analysis did not aware of randomization. at first, a 3-day recall food questionnaire was taken from two groups. From the day, the subjects tested positive, they were asked to start supplementation for 4 weeks and return after that to take the first dose of the vaccine. Subjects were asked to continue to use supplements after the first vaccination. After 6 to 8 weeks, patients came back for another vaccination dose and were again asked to use the supplement for 4 weeks again, after that subjects were asked to come for a blood test.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 500 is above the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Sulaimany Polytechnic university is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
participants with COVID-19 positive tests.
Exclusion criteria:
The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast for 14-16 weeks.
Combination Product: Vitamin-D
The control group took a placebo prepared with the same shape and size of supplements.
Combination Product: Vitamin-D
The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast for 14-16 weeks.
Vit-D supplementation has role in reduce BioNTech, Pfizer vaccine side effect
Vitamin D supplement was given for 16 weeks
Time frame: 16 weeks
Vit-D supplementation has role in improve IgG titer
Vitamin D supplement was given for 16 weeks
Time frame: 16 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sulaimany Polytechnic university